FOXM1 and meningioma: HM meningiomas were clinically aggressive cases with poor outcomes enriched for FOXM1 cell proliferation pathways.37 Subsequent reanalysis of the HM group revealed 2 distinct subgroups within it: one subgroup enriched in pathways related to macromolecule metabolism (resembling the MG3 Hypermetabolic meningiomas with intermediate to poor outcomes) and the other enriched for cell cycle pathways that had the worst clinical outcomes (similar to the MG4 Proliferative meningiomas).